LeonaBio, Inc. (LONA) - Total Liabilities
Based on the latest financial reports, LeonaBio, Inc. (LONA) has total liabilities worth $22.29 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LeonaBio, Inc. (LONA) equity growth momentum to track the company's year-over-year net asset growth rate.
LeonaBio, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
LeonaBio, Inc. Competitors by Total Liabilities
The table below lists competitors of LeonaBio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norcod As
OL:NCOD
|
Norway | Nkr335.97 Million |
|
Oceanic Iron Ore Corp
V:FEO
|
Canada | CA$58.94 Million |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
USA | $1.92 Billion |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
USA | $190.34 Million |
|
ENERGY TRANSITION MINERAL
F:G7PA
|
Germany | €6.17 Million |
|
Mallcom (India) Limited
NSE:MALLCOM
|
India | Rs1.80 Billion |
|
Tex Cycle Technology M Bhd
KLSE:0089
|
Malaysia | RM93.04 Million |
|
A-Jin Industry Co Ltd
KQ:013310
|
Korea | ₩1.15 Trillion |
Liability Composition Analysis (2018–2025)
This chart breaks down LeonaBio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LONA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LeonaBio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LeonaBio, Inc. (2018–2025)
The table below shows the annual total liabilities of LeonaBio, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.36 Million | +361.77% |
| 2024-12-31 | $13.94 Million | -53.63% |
| 2023-12-31 | $30.06 Million | +30.59% |
| 2022-12-31 | $23.02 Million | +110.69% |
| 2021-12-31 | $10.92 Million | +106.85% |
| 2020-12-31 | $5.28 Million | -75.90% |
| 2019-12-31 | $21.91 Million | +10.55% |
| 2018-12-31 | $19.82 Million | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more